TY  - JOUR
AU  - Panić, Bojana
AU  - Jovanović, Marija
AU  - Lukić, Vera
AU  - Vučićević, Katarina
AU  - Miljković, Branislava
AU  - Milovanović, Srđan
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5040
AB  - Purpose: The goal of the study was to examine clozapine (CLZ) and norclozapine (NCLZ) therapeutic drug monitoring (TDM) data and associated sources of pharmacokinetic variability, particularly the impact of valproic acid (VPA) use. Methods: This study included 126 patients with psychiatric disorders on mono- or co-therapy with CLZ. Patients’ data during routine TDM were collected retrospectively from clinical records. The descriptive and statistical analysis was computed using IBM SPSS Statistics software (version 22, NY, USA). Multiple linear regression, based on the last observations, was used to assess correlation between demographic characteristics, life habits and co-therapy with dose-corrected serum levels (C/D) of CLZ and NCLZ, as well as CLZ/NCLZ. Results: A total of 295 CLZ concentrations were measured in 126 patients, with a mean of 275.5 ± 174.4 µg/L, while 124 NCLZ concentrations were determined in 74 patients, with a mean of 194.6 ± 149.8 µg/L. A statistically significant effect on ln-transformed CLZ C/D was confirmed for sex and smoking, whereas sex, smoking and VPA therapy were associated with ln-transformed NCLZ C/D. According to the final models, lower values of NCLZ C/D for about 45.9% can be expected in patients receiving VPA. Concomitant use of VPA was the only factor detected to contribute in CLZ/NCLZ variability. Conclusion: The results of this study may help clinicians interpret TDM data and optimize CLZ dosing regimens, especially in patients concomitantly treated with VPA. Our results show that VPA primarily decreases NCLZ levels, while alteration of the parent drug is not statistically significant.
PB  - Springer
T2  - European Journal of Clinical Pharmacology
T1  - Association of clozapine and norclozapine levels with patient and therapy characteristics—focus on interaction with valproic acid
DO  - 10.1007/s00228-023-03569-2
ER  - 

@article{
author = "Panić, Bojana and Jovanović, Marija and Lukić, Vera and Vučićević, Katarina and Miljković, Branislava and Milovanović, Srđan",
year = "2023",
abstract = "Purpose: The goal of the study was to examine clozapine (CLZ) and norclozapine (NCLZ) therapeutic drug monitoring (TDM) data and associated sources of pharmacokinetic variability, particularly the impact of valproic acid (VPA) use. Methods: This study included 126 patients with psychiatric disorders on mono- or co-therapy with CLZ. Patients’ data during routine TDM were collected retrospectively from clinical records. The descriptive and statistical analysis was computed using IBM SPSS Statistics software (version 22, NY, USA). Multiple linear regression, based on the last observations, was used to assess correlation between demographic characteristics, life habits and co-therapy with dose-corrected serum levels (C/D) of CLZ and NCLZ, as well as CLZ/NCLZ. Results: A total of 295 CLZ concentrations were measured in 126 patients, with a mean of 275.5 ± 174.4 µg/L, while 124 NCLZ concentrations were determined in 74 patients, with a mean of 194.6 ± 149.8 µg/L. A statistically significant effect on ln-transformed CLZ C/D was confirmed for sex and smoking, whereas sex, smoking and VPA therapy were associated with ln-transformed NCLZ C/D. According to the final models, lower values of NCLZ C/D for about 45.9% can be expected in patients receiving VPA. Concomitant use of VPA was the only factor detected to contribute in CLZ/NCLZ variability. Conclusion: The results of this study may help clinicians interpret TDM data and optimize CLZ dosing regimens, especially in patients concomitantly treated with VPA. Our results show that VPA primarily decreases NCLZ levels, while alteration of the parent drug is not statistically significant.",
publisher = "Springer",
journal = "European Journal of Clinical Pharmacology",
title = "Association of clozapine and norclozapine levels with patient and therapy characteristics—focus on interaction with valproic acid",
doi = "10.1007/s00228-023-03569-2"
}

Panić, B., Jovanović, M., Lukić, V., Vučićević, K., Miljković, B.,& Milovanović, S.. (2023). Association of clozapine and norclozapine levels with patient and therapy characteristics—focus on interaction with valproic acid. in European Journal of Clinical Pharmacology
Springer..
https://doi.org/10.1007/s00228-023-03569-2

Panić B, Jovanović M, Lukić V, Vučićević K, Miljković B, Milovanović S. Association of clozapine and norclozapine levels with patient and therapy characteristics—focus on interaction with valproic acid. in European Journal of Clinical Pharmacology. 2023;.
doi:10.1007/s00228-023-03569-2 .

Panić, Bojana, Jovanović, Marija, Lukić, Vera, Vučićević, Katarina, Miljković, Branislava, Milovanović, Srđan, "Association of clozapine and norclozapine levels with patient and therapy characteristics—focus on interaction with valproic acid" in European Journal of Clinical Pharmacology (2023),
https://doi.org/10.1007/s00228-023-03569-2 . .

TY  - CONF
AU  - Panić, Bojana
AU  - Jovanović, Marija
AU  - Lukić, Vera
AU  - Bulat, Zorica
AU  - Vučićević, Katarina
AU  - Miljković, Branislava
AU  - Milovanović, Srđan
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4507
AB  - The atypical antipsychotic clozapine (CLZ) is primarily used for the treatment-
resistant schizophrenia. Due to low therapeutic index and high pharmacokinetic variability,
therapeutic drug monitoring (TDM) is highly recommended (1). The aim of this retrospective
study was to analyze TDM data of CLZ and its active metabolite norclozapine (NCLZ) in adult
patient with schizophrenia. The study included CLZ TDM data obtained from 69 patients (22-
67 years) treated at the Clinic for Psychiatry, Clinical Center of Serbia, while NCLZ data were
available from 43 patients. Serum concentrations were determined at the Institute of
Forensic Medicine, Belgrade, Serbia using liquid chromatography with tandem mass
spectrometry (LC‐MS/MS). Statistical analysis was performed by SPSS software® (version
18). The daily doses of CLZ ranged between 37.5 and 600 mg. The mean value of CLZ and
NCLZ levels were 0.285 ± 0.174 mg/L and 0.189 ± 0.132 mg/L, respectively. 73.06% and
26.83% of measured CLZ and NCLZ concentrations were outside reference range (mostly
below), respectively. Significant positive correlation (p<0.05) was observed between daily
dose and CLZ levels, as well as between dose and NCLZ levels. Significant correlations of dose
and CLZ levels were confirmed in males and females, smokers and nonsmokers, separately.
Parent drug and metabolite levels varied 13 and 16-fold in patients receiving 300 mg/day,
respectively. The results indicate considerable variability in CLZ and NCLZ concentrations in
adult patients with schizophrenia, and positive association with dose. Further multivariate
analysis is required to assess, in addition to dose, potential influences of other patient and
co-therapy factors.
AB  - Atipični antipsihotik klozapin (clozapine, CLZ) se primarno koristi kod shizofrenije
rezistentne na terapiju. Zbog niskog terapijskog indeksa i velike farmakokinetičke
varijabilnosti, terapijsko prać enje lekova (therapeutic drug monitoring, TDM) se preporučuje
(1). Cilj ovog retrospektivnog istraživanja je bio ispitivanje TDM podataka o CLZ i njegovom
aktivnom metabolitu norklozapinu (norclozapine, NCLZ) kod odraslih pacijenata sa
shizofrenijom. Studija je obuhvatila TDM podatke o CLZ dobijene od 69 pacijenata (22-67
godina) lečenih na Klinici za psihijatriju Kliničkog centra Srbije, dok su podaci za NCLZ bili
dostupni od 43 pacijenta. Koncentracije u serumu su merene na Institutu za sudsku
medicinu, Beograd, Srbija tečnom hromatografijom sa tandem masenom spektrometrijom
(LC‐MS/MS). Statistička analiza je izvršena pomoć u softvera SPSS® (verzija 18). Dnevne doze
CLZ kretale su se između 37,5 i 600 mg. Srednja vrednost je bila 0,285 ± 0,174 mg/L za CLZ i
0,189 ± 0,132 mg/L za NCLZ. 73,06% i 26,83% izmerenih koncentracija CLZ i NCLZ bile su
izvan referentnog opsega (uglavnom ispod), respektivno. Detektovana je pozitivna korelacija
(p<0,05) između dnevne doze i nivoa CLZ, kao i doze i nivoa NCLZ. Značajna korelacija doze i
nivoa CLZ je potvrđena i pri odvojenom ispitivanju kod muškaraca, žena, pušača i nepušača.
Nivoi leka i metabolita varirali su 13 i 16 puta kod pacijenata koji su uzimali 300 mg/dan,
respektivno. Rezultati ukazuju na značajnu varijabilnost u koncentracijama CLZ i NCLZ kod
odraslih pacijenata sa shizofrenijom i pozitivnu povezanost sa dozom. Potrebna je dalja
multivarijantna analiza da bi se procenili, pored doze, potencijalni uticaji karakteristika
pacijenata i kombinovane terapije.
PB  - Savez farmaceutskih udruženja Srbije (SFUS)
C3  - Arhiv za farmaciju
T1  - Analysis of clozapine and norclozapine concentrations in adult patients with schizophrenia
T1  - Analiza koncentracija klozapina i norklozapina kod odraslih pacijenata sa shizofrenijom
VL  - 72
IS  - 4 suplement
SP  - S225
EP  - S226
UR  - https://hdl.handle.net/21.15107/rcub_farfar_4507
ER  - 

@conference{
author = "Panić, Bojana and Jovanović, Marija and Lukić, Vera and Bulat, Zorica and Vučićević, Katarina and Miljković, Branislava and Milovanović, Srđan",
year = "2022",
abstract = "The atypical antipsychotic clozapine (CLZ) is primarily used for the treatment-
resistant schizophrenia. Due to low therapeutic index and high pharmacokinetic variability,
therapeutic drug monitoring (TDM) is highly recommended (1). The aim of this retrospective
study was to analyze TDM data of CLZ and its active metabolite norclozapine (NCLZ) in adult
patient with schizophrenia. The study included CLZ TDM data obtained from 69 patients (22-
67 years) treated at the Clinic for Psychiatry, Clinical Center of Serbia, while NCLZ data were
available from 43 patients. Serum concentrations were determined at the Institute of
Forensic Medicine, Belgrade, Serbia using liquid chromatography with tandem mass
spectrometry (LC‐MS/MS). Statistical analysis was performed by SPSS software® (version
18). The daily doses of CLZ ranged between 37.5 and 600 mg. The mean value of CLZ and
NCLZ levels were 0.285 ± 0.174 mg/L and 0.189 ± 0.132 mg/L, respectively. 73.06% and
26.83% of measured CLZ and NCLZ concentrations were outside reference range (mostly
below), respectively. Significant positive correlation (p<0.05) was observed between daily
dose and CLZ levels, as well as between dose and NCLZ levels. Significant correlations of dose
and CLZ levels were confirmed in males and females, smokers and nonsmokers, separately.
Parent drug and metabolite levels varied 13 and 16-fold in patients receiving 300 mg/day,
respectively. The results indicate considerable variability in CLZ and NCLZ concentrations in
adult patients with schizophrenia, and positive association with dose. Further multivariate
analysis is required to assess, in addition to dose, potential influences of other patient and
co-therapy factors., Atipični antipsihotik klozapin (clozapine, CLZ) se primarno koristi kod shizofrenije
rezistentne na terapiju. Zbog niskog terapijskog indeksa i velike farmakokinetičke
varijabilnosti, terapijsko prać enje lekova (therapeutic drug monitoring, TDM) se preporučuje
(1). Cilj ovog retrospektivnog istraživanja je bio ispitivanje TDM podataka o CLZ i njegovom
aktivnom metabolitu norklozapinu (norclozapine, NCLZ) kod odraslih pacijenata sa
shizofrenijom. Studija je obuhvatila TDM podatke o CLZ dobijene od 69 pacijenata (22-67
godina) lečenih na Klinici za psihijatriju Kliničkog centra Srbije, dok su podaci za NCLZ bili
dostupni od 43 pacijenta. Koncentracije u serumu su merene na Institutu za sudsku
medicinu, Beograd, Srbija tečnom hromatografijom sa tandem masenom spektrometrijom
(LC‐MS/MS). Statistička analiza je izvršena pomoć u softvera SPSS® (verzija 18). Dnevne doze
CLZ kretale su se između 37,5 i 600 mg. Srednja vrednost je bila 0,285 ± 0,174 mg/L za CLZ i
0,189 ± 0,132 mg/L za NCLZ. 73,06% i 26,83% izmerenih koncentracija CLZ i NCLZ bile su
izvan referentnog opsega (uglavnom ispod), respektivno. Detektovana je pozitivna korelacija
(p<0,05) između dnevne doze i nivoa CLZ, kao i doze i nivoa NCLZ. Značajna korelacija doze i
nivoa CLZ je potvrđena i pri odvojenom ispitivanju kod muškaraca, žena, pušača i nepušača.
Nivoi leka i metabolita varirali su 13 i 16 puta kod pacijenata koji su uzimali 300 mg/dan,
respektivno. Rezultati ukazuju na značajnu varijabilnost u koncentracijama CLZ i NCLZ kod
odraslih pacijenata sa shizofrenijom i pozitivnu povezanost sa dozom. Potrebna je dalja
multivarijantna analiza da bi se procenili, pored doze, potencijalni uticaji karakteristika
pacijenata i kombinovane terapije.",
publisher = "Savez farmaceutskih udruženja Srbije (SFUS)",
journal = "Arhiv za farmaciju",
title = "Analysis of clozapine and norclozapine concentrations in adult patients with schizophrenia, Analiza koncentracija klozapina i norklozapina kod odraslih pacijenata sa shizofrenijom",
volume = "72",
number = "4 suplement",
pages = "S225-S226",
url = "https://hdl.handle.net/21.15107/rcub_farfar_4507"
}

Panić, B., Jovanović, M., Lukić, V., Bulat, Z., Vučićević, K., Miljković, B.,& Milovanović, S.. (2022). Analysis of clozapine and norclozapine concentrations in adult patients with schizophrenia. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije (SFUS)., 72(4 suplement), S225-S226.
https://hdl.handle.net/21.15107/rcub_farfar_4507

Panić B, Jovanović M, Lukić V, Bulat Z, Vučićević K, Miljković B, Milovanović S. Analysis of clozapine and norclozapine concentrations in adult patients with schizophrenia. in Arhiv za farmaciju. 2022;72(4 suplement):S225-S226.
https://hdl.handle.net/21.15107/rcub_farfar_4507 .

Panić, Bojana, Jovanović, Marija, Lukić, Vera, Bulat, Zorica, Vučićević, Katarina, Miljković, Branislava, Milovanović, Srđan, "Analysis of clozapine and norclozapine concentrations in adult patients with schizophrenia" in Arhiv za farmaciju, 72, no. 4 suplement (2022):S225-S226,
https://hdl.handle.net/21.15107/rcub_farfar_4507 .

TY  - JOUR
AU  - Vidović, Bojana
AU  - Milovanović, Srđan
AU  - Stefanović, Aleksandra
AU  - Kotur-Stevuljević, Jelena
AU  - Takić, Marija
AU  - Debeljak-Martacić, Jasmina
AU  - Pantović, Maja
AU  - Đorđević, Brižita
PY  - 2017
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2957
AB  - Adiponectin is an adipocyte-derived plasma protein with insulin-sensitizing and anti-inflammatory properties and is suggested to be a biomarker of metabolic disturbances. The aim of this study was to investigate the effects of alphalipoic acid (ALA) on plasma adiponectin and some metabolic risk factors in patients with schizophrenia. The plasma adipokine levels (adiponectin and leptin), routine biochemical and anthropometric parameters, markers of oxidative stress, and the serum phospholipid fatty acid profile in eighteen schizophrenic patients at baseline, in the middle, and at the end of a 3-month long supplementation period with ALA (500 mg daily) were determined. A significant increase in the plasma adiponectin concentrations, as well as a decrease in fasting glucose and aspartate aminotransferase activity (AST), was found. Baseline AST activity was independently correlated with the adiponectin concentrations. Our data show that ALA can improve plasma adiponectin levels and may play a potential role in the treatment of metabolic risk factor in patients with schizophrenia. Future randomized controlled trials are needed to confirm these preliminary investigations.
PB  - Mary Ann Liebert, Inc, New Rochelle
T2  - Journal of Medicinal Food
T1  - Effects of Alpha-Lipoic Acid Supplementation on Plasma Adiponectin Levels and Some Metabolic Risk Factors in Patients with Schizophrenia
VL  - 20
IS  - 1
SP  - 79
EP  - 85
DO  - 10.1089/jmf.2016.0070
ER  - 

@article{
author = "Vidović, Bojana and Milovanović, Srđan and Stefanović, Aleksandra and Kotur-Stevuljević, Jelena and Takić, Marija and Debeljak-Martacić, Jasmina and Pantović, Maja and Đorđević, Brižita",
year = "2017",
abstract = "Adiponectin is an adipocyte-derived plasma protein with insulin-sensitizing and anti-inflammatory properties and is suggested to be a biomarker of metabolic disturbances. The aim of this study was to investigate the effects of alphalipoic acid (ALA) on plasma adiponectin and some metabolic risk factors in patients with schizophrenia. The plasma adipokine levels (adiponectin and leptin), routine biochemical and anthropometric parameters, markers of oxidative stress, and the serum phospholipid fatty acid profile in eighteen schizophrenic patients at baseline, in the middle, and at the end of a 3-month long supplementation period with ALA (500 mg daily) were determined. A significant increase in the plasma adiponectin concentrations, as well as a decrease in fasting glucose and aspartate aminotransferase activity (AST), was found. Baseline AST activity was independently correlated with the adiponectin concentrations. Our data show that ALA can improve plasma adiponectin levels and may play a potential role in the treatment of metabolic risk factor in patients with schizophrenia. Future randomized controlled trials are needed to confirm these preliminary investigations.",
publisher = "Mary Ann Liebert, Inc, New Rochelle",
journal = "Journal of Medicinal Food",
title = "Effects of Alpha-Lipoic Acid Supplementation on Plasma Adiponectin Levels and Some Metabolic Risk Factors in Patients with Schizophrenia",
volume = "20",
number = "1",
pages = "79-85",
doi = "10.1089/jmf.2016.0070"
}

Vidović, B., Milovanović, S., Stefanović, A., Kotur-Stevuljević, J., Takić, M., Debeljak-Martacić, J., Pantović, M.,& Đorđević, B.. (2017). Effects of Alpha-Lipoic Acid Supplementation on Plasma Adiponectin Levels and Some Metabolic Risk Factors in Patients with Schizophrenia. in Journal of Medicinal Food
Mary Ann Liebert, Inc, New Rochelle., 20(1), 79-85.
https://doi.org/10.1089/jmf.2016.0070

Vidović B, Milovanović S, Stefanović A, Kotur-Stevuljević J, Takić M, Debeljak-Martacić J, Pantović M, Đorđević B. Effects of Alpha-Lipoic Acid Supplementation on Plasma Adiponectin Levels and Some Metabolic Risk Factors in Patients with Schizophrenia. in Journal of Medicinal Food. 2017;20(1):79-85.
doi:10.1089/jmf.2016.0070 .

Vidović, Bojana, Milovanović, Srđan, Stefanović, Aleksandra, Kotur-Stevuljević, Jelena, Takić, Marija, Debeljak-Martacić, Jasmina, Pantović, Maja, Đorđević, Brižita, "Effects of Alpha-Lipoic Acid Supplementation on Plasma Adiponectin Levels and Some Metabolic Risk Factors in Patients with Schizophrenia" in Journal of Medicinal Food, 20, no. 1 (2017):79-85,
https://doi.org/10.1089/jmf.2016.0070 . .

TY  - JOUR
AU  - Vidović, Bojana
AU  - Milovanović, Srđan
AU  - Đorđević, Brižita
AU  - Kotur-Stevuljević, Jelena
AU  - Stefanović, Aleksandra
AU  - Ivanišević, Jasmina
AU  - Miljković, Milica
AU  - Spasić, Slavica
AU  - Stojanović, Dragana
AU  - Pantović, Maja
PY  - 2014
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2095
AB  - Background: The purpose of this study was to examine the effects of alpha-lipoic acid (LA) supplementation on oxidative stress markers in patients with schizophrenia. Subjects and methods: Eighteen (18) medicated patients with schizophrenia and 38 healthy controls received daily supplements of LA (500 mg/day) for three months. At baseline, 45th and 90th days of supplementation, venous blood collected for analysis of oxidative stress markers [superoxide anion (O-2(center dot-)), thiobarbituric acid-reactive substances (TBARS) and advanced oxidation protein products (AOPP)] and antioxidative defense markers [superoxide dismutase (SOD), total sulfhydryl groups (-SH) and total antioxidant status (TAS)]. Results: Increased plasma TBARS, TAS, SH groups levels and SOD activity were found in schizophrenic patients compared to control group. LA supplementation significantly reduced TBARS, AOPP and improved TAS levels in healthy subjects, while there were no significant differences in patients group. SH groups increased after 45 days and decreased to baseline levels after 90 days of supplementation in the control group. SOD activity decreased significantly in patients group after 45 days and 90 days of supplementation. After initial rose SOD activity in control group, decreased to baseline levels found after 90 days. Conclusion: LA supplementation decreased lipid peroxidation and oxidative damage of proteins and improved non-enzymatic antioxidant capacity in healthy controls. No significant changes were observed on oxidative damage in patients with schizophrenia.
PB  - Medicinska Naklada, Zagreb
T2  - Psychiatria Danubina
T1  - Effect of alpha-lipoic acid supplementation on oxidative stress markers and antioxidative defense in patients with schizophrenia
VL  - 26
IS  - 3
SP  - 205
EP  - 213
UR  - https://hdl.handle.net/21.15107/rcub_farfar_2095
ER  - 

@article{
author = "Vidović, Bojana and Milovanović, Srđan and Đorđević, Brižita and Kotur-Stevuljević, Jelena and Stefanović, Aleksandra and Ivanišević, Jasmina and Miljković, Milica and Spasić, Slavica and Stojanović, Dragana and Pantović, Maja",
year = "2014",
abstract = "Background: The purpose of this study was to examine the effects of alpha-lipoic acid (LA) supplementation on oxidative stress markers in patients with schizophrenia. Subjects and methods: Eighteen (18) medicated patients with schizophrenia and 38 healthy controls received daily supplements of LA (500 mg/day) for three months. At baseline, 45th and 90th days of supplementation, venous blood collected for analysis of oxidative stress markers [superoxide anion (O-2(center dot-)), thiobarbituric acid-reactive substances (TBARS) and advanced oxidation protein products (AOPP)] and antioxidative defense markers [superoxide dismutase (SOD), total sulfhydryl groups (-SH) and total antioxidant status (TAS)]. Results: Increased plasma TBARS, TAS, SH groups levels and SOD activity were found in schizophrenic patients compared to control group. LA supplementation significantly reduced TBARS, AOPP and improved TAS levels in healthy subjects, while there were no significant differences in patients group. SH groups increased after 45 days and decreased to baseline levels after 90 days of supplementation in the control group. SOD activity decreased significantly in patients group after 45 days and 90 days of supplementation. After initial rose SOD activity in control group, decreased to baseline levels found after 90 days. Conclusion: LA supplementation decreased lipid peroxidation and oxidative damage of proteins and improved non-enzymatic antioxidant capacity in healthy controls. No significant changes were observed on oxidative damage in patients with schizophrenia.",
publisher = "Medicinska Naklada, Zagreb",
journal = "Psychiatria Danubina",
title = "Effect of alpha-lipoic acid supplementation on oxidative stress markers and antioxidative defense in patients with schizophrenia",
volume = "26",
number = "3",
pages = "205-213",
url = "https://hdl.handle.net/21.15107/rcub_farfar_2095"
}

Vidović, B., Milovanović, S., Đorđević, B., Kotur-Stevuljević, J., Stefanović, A., Ivanišević, J., Miljković, M., Spasić, S., Stojanović, D.,& Pantović, M.. (2014). Effect of alpha-lipoic acid supplementation on oxidative stress markers and antioxidative defense in patients with schizophrenia. in Psychiatria Danubina
Medicinska Naklada, Zagreb., 26(3), 205-213.
https://hdl.handle.net/21.15107/rcub_farfar_2095

Vidović B, Milovanović S, Đorđević B, Kotur-Stevuljević J, Stefanović A, Ivanišević J, Miljković M, Spasić S, Stojanović D, Pantović M. Effect of alpha-lipoic acid supplementation on oxidative stress markers and antioxidative defense in patients with schizophrenia. in Psychiatria Danubina. 2014;26(3):205-213.
https://hdl.handle.net/21.15107/rcub_farfar_2095 .

Vidović, Bojana, Milovanović, Srđan, Đorđević, Brižita, Kotur-Stevuljević, Jelena, Stefanović, Aleksandra, Ivanišević, Jasmina, Miljković, Milica, Spasić, Slavica, Stojanović, Dragana, Pantović, Maja, "Effect of alpha-lipoic acid supplementation on oxidative stress markers and antioxidative defense in patients with schizophrenia" in Psychiatria Danubina, 26, no. 3 (2014):205-213,
https://hdl.handle.net/21.15107/rcub_farfar_2095 .

TY  - JOUR
AU  - Vidović, Bojana
AU  - Stefanović, Aleksandra
AU  - Milovanović, Srđan
AU  - Đorđević, Brižita
AU  - Kotur-Stevuljević, Jelena
AU  - Ivanišević, Jasmina
AU  - Miljković, Milica
AU  - Spasić, Slavica
PY  - 2014
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2230
AB  - Background. The purpose of this study was to assess oxidative stress status parameters and their possible associations with traditional cardiovascular risk factors in patients with schizophrenia, as well as their potential for patient-control discrimination. Methods. Fasting glucose, lipid profi le and oxidative stress status parameters were assessed in 30 schizophrenic patients with atypical antipsychotic therapy and 60 control subjects. Results. Malondialdehyde (MDA), pro-oxidant/antioxidant balance (PAB) and total anti-oxidant status (TAS) were significantly higher whereas total sulfhydryl (SH) groups were significantly lower in schizophrenic patients vs. control group. Higher serum PAB values showed an independent association with schizophrenia. The addition of PAB to conventional risk factors improved discrimination between healthy control subjects and patients. Conclusion. Increased oxidative stress and changed lipid profi le parameters are associated in schizophrenic patients and may indicate risk for atherosclerosis. The serum PAB level may reflect the levels of oxidative stress in schizophrenia and improve discrimination of patients from controls.
PB  - Informa Healthcare, London
T2  - Scandinavian Journal of Clinical and Laboratory Investigation
T1  - Associations of oxidative stress status parameters with traditional cardiovascular disease risk factors in patients with schizophrenia
VL  - 74
IS  - 3
SP  - 184
EP  - 191
DO  - 10.3109/00365513.2013.873947
ER  - 

@article{
author = "Vidović, Bojana and Stefanović, Aleksandra and Milovanović, Srđan and Đorđević, Brižita and Kotur-Stevuljević, Jelena and Ivanišević, Jasmina and Miljković, Milica and Spasić, Slavica",
year = "2014",
abstract = "Background. The purpose of this study was to assess oxidative stress status parameters and their possible associations with traditional cardiovascular risk factors in patients with schizophrenia, as well as their potential for patient-control discrimination. Methods. Fasting glucose, lipid profi le and oxidative stress status parameters were assessed in 30 schizophrenic patients with atypical antipsychotic therapy and 60 control subjects. Results. Malondialdehyde (MDA), pro-oxidant/antioxidant balance (PAB) and total anti-oxidant status (TAS) were significantly higher whereas total sulfhydryl (SH) groups were significantly lower in schizophrenic patients vs. control group. Higher serum PAB values showed an independent association with schizophrenia. The addition of PAB to conventional risk factors improved discrimination between healthy control subjects and patients. Conclusion. Increased oxidative stress and changed lipid profi le parameters are associated in schizophrenic patients and may indicate risk for atherosclerosis. The serum PAB level may reflect the levels of oxidative stress in schizophrenia and improve discrimination of patients from controls.",
publisher = "Informa Healthcare, London",
journal = "Scandinavian Journal of Clinical and Laboratory Investigation",
title = "Associations of oxidative stress status parameters with traditional cardiovascular disease risk factors in patients with schizophrenia",
volume = "74",
number = "3",
pages = "184-191",
doi = "10.3109/00365513.2013.873947"
}

Vidović, B., Stefanović, A., Milovanović, S., Đorđević, B., Kotur-Stevuljević, J., Ivanišević, J., Miljković, M.,& Spasić, S.. (2014). Associations of oxidative stress status parameters with traditional cardiovascular disease risk factors in patients with schizophrenia. in Scandinavian Journal of Clinical and Laboratory Investigation
Informa Healthcare, London., 74(3), 184-191.
https://doi.org/10.3109/00365513.2013.873947

Vidović B, Stefanović A, Milovanović S, Đorđević B, Kotur-Stevuljević J, Ivanišević J, Miljković M, Spasić S. Associations of oxidative stress status parameters with traditional cardiovascular disease risk factors in patients with schizophrenia. in Scandinavian Journal of Clinical and Laboratory Investigation. 2014;74(3):184-191.
doi:10.3109/00365513.2013.873947 .

Vidović, Bojana, Stefanović, Aleksandra, Milovanović, Srđan, Đorđević, Brižita, Kotur-Stevuljević, Jelena, Ivanišević, Jasmina, Miljković, Milica, Spasić, Slavica, "Associations of oxidative stress status parameters with traditional cardiovascular disease risk factors in patients with schizophrenia" in Scandinavian Journal of Clinical and Laboratory Investigation, 74, no. 3 (2014):184-191,
https://doi.org/10.3109/00365513.2013.873947 . .

TY  - JOUR
AU  - Milošević-Georgiev, Andrijana
AU  - Krajnović, Dušanka
AU  - Milovanović, Srđan
AU  - Ignjatović, Svetlana
AU  - Đurić, Dušan
AU  - Marinković, Valentina
PY  - 2013
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2059
AB  - Introduction. Every clinical trial has to meet all ethical criteria in addition to the scientific ones. The basic ethical principles in the clinical trials are the following: nonmaleficence, beneficence, respect for autonomy and the principle of justice. Objective. The aim of the study was to analyze clinical cases with the outcomes leading to the changes in regulatory­ethical framework related to the clinical trials, as well as the outcomes of key clinical trials that influenced the introduction of the ethical principles into clinical trials. Methods. This was a descriptive research (methods of analysis and documentation; desk analysis of the secondary data). Results. By analyzing the cases from the secondary sources as well as clinical and ethical outcomes, it may be noticed that the codes, declarations and regulations have been often preceded by certain events that caused their adoption. Moral concern and public awareness of the ethical issues have initiated not only the development of numerous guidelines, codes, and declarations, but also their incorporation into the legislative acts. Conclusion. It is desirable that ethical instruments become legally binding documents, because only in this way will be possible to control all phases of the clinical trials and prevent abuse of the respondents.
AB  - Uvod. Svako kliničko ispitivanje, pored naučnih, mora da zadovolji i etičke kriterijume. Osnovni etički principi u kliničkim ispitivanjima su: neškodljivost, dobročinstvo, poštovanje autonomije i princip pravednosti. Cilj rada. Cilj rada je bio da se analiziraju klinički slučajevi čiji su ishodi doveli do promena u regulatorno­etičkom okviru u vezi s kliničkim ispitivanjima i ishodi kliničkih ispitivanja koja su uticala na uvođenje etičkih principa. Metode rada. Istraživanje je bilo deskriptivno, a primenjene su metoda dokumentacione analize i desk­analiza sekundarnih podataka. Rezultati. Analizom slučajeva iz sekundarnih izvora, te kliničkih i etičkih ishoda, može se primetiti da su kodeksima, deklaracijama i pravilima prethodili događaji koji su uzrokovali njihovo donošenje. Moralna briga i svest javnosti o etičkim problemima pokrenule su razvoj brojnih smernica, kodeksa i deklaracija i njihovo uvrštavanje u zakonska akta. Zaključak. Ukoliko se regulativa svih faza kliničkih ispitivanja zasniva na etičkim postavkama, kontrola i ishod su bazirani na humanim osnovama i prava su mera dobrobiti društva i pojedinca.
PB  - Srpsko lekarsko društvo, Beograd
T2  - Srpski arhiv za celokupno lekarstvo
T1  - Analysis of regulatory-ethical framework of clinical trials
T1  - Analiza razvoja regulatorno-etičkog okvira za klinička ispitivanja
VL  - 141
IS  - 9-10
SP  - 659
EP  - 666
DO  - 10.2298/SARH1310659M
ER  - 

@article{
author = "Milošević-Georgiev, Andrijana and Krajnović, Dušanka and Milovanović, Srđan and Ignjatović, Svetlana and Đurić, Dušan and Marinković, Valentina",
year = "2013",
abstract = "Introduction. Every clinical trial has to meet all ethical criteria in addition to the scientific ones. The basic ethical principles in the clinical trials are the following: nonmaleficence, beneficence, respect for autonomy and the principle of justice. Objective. The aim of the study was to analyze clinical cases with the outcomes leading to the changes in regulatory­ethical framework related to the clinical trials, as well as the outcomes of key clinical trials that influenced the introduction of the ethical principles into clinical trials. Methods. This was a descriptive research (methods of analysis and documentation; desk analysis of the secondary data). Results. By analyzing the cases from the secondary sources as well as clinical and ethical outcomes, it may be noticed that the codes, declarations and regulations have been often preceded by certain events that caused their adoption. Moral concern and public awareness of the ethical issues have initiated not only the development of numerous guidelines, codes, and declarations, but also their incorporation into the legislative acts. Conclusion. It is desirable that ethical instruments become legally binding documents, because only in this way will be possible to control all phases of the clinical trials and prevent abuse of the respondents., Uvod. Svako kliničko ispitivanje, pored naučnih, mora da zadovolji i etičke kriterijume. Osnovni etički principi u kliničkim ispitivanjima su: neškodljivost, dobročinstvo, poštovanje autonomije i princip pravednosti. Cilj rada. Cilj rada je bio da se analiziraju klinički slučajevi čiji su ishodi doveli do promena u regulatorno­etičkom okviru u vezi s kliničkim ispitivanjima i ishodi kliničkih ispitivanja koja su uticala na uvođenje etičkih principa. Metode rada. Istraživanje je bilo deskriptivno, a primenjene su metoda dokumentacione analize i desk­analiza sekundarnih podataka. Rezultati. Analizom slučajeva iz sekundarnih izvora, te kliničkih i etičkih ishoda, može se primetiti da su kodeksima, deklaracijama i pravilima prethodili događaji koji su uzrokovali njihovo donošenje. Moralna briga i svest javnosti o etičkim problemima pokrenule su razvoj brojnih smernica, kodeksa i deklaracija i njihovo uvrštavanje u zakonska akta. Zaključak. Ukoliko se regulativa svih faza kliničkih ispitivanja zasniva na etičkim postavkama, kontrola i ishod su bazirani na humanim osnovama i prava su mera dobrobiti društva i pojedinca.",
publisher = "Srpsko lekarsko društvo, Beograd",
journal = "Srpski arhiv za celokupno lekarstvo",
title = "Analysis of regulatory-ethical framework of clinical trials, Analiza razvoja regulatorno-etičkog okvira za klinička ispitivanja",
volume = "141",
number = "9-10",
pages = "659-666",
doi = "10.2298/SARH1310659M"
}

Milošević-Georgiev, A., Krajnović, D., Milovanović, S., Ignjatović, S., Đurić, D.,& Marinković, V.. (2013). Analysis of regulatory-ethical framework of clinical trials. in Srpski arhiv za celokupno lekarstvo
Srpsko lekarsko društvo, Beograd., 141(9-10), 659-666.
https://doi.org/10.2298/SARH1310659M

Milošević-Georgiev A, Krajnović D, Milovanović S, Ignjatović S, Đurić D, Marinković V. Analysis of regulatory-ethical framework of clinical trials. in Srpski arhiv za celokupno lekarstvo. 2013;141(9-10):659-666.
doi:10.2298/SARH1310659M .

Milošević-Georgiev, Andrijana, Krajnović, Dušanka, Milovanović, Srđan, Ignjatović, Svetlana, Đurić, Dušan, Marinković, Valentina, "Analysis of regulatory-ethical framework of clinical trials" in Srpski arhiv za celokupno lekarstvo, 141, no. 9-10 (2013):659-666,
https://doi.org/10.2298/SARH1310659M . .

TY  - JOUR
AU  - Vidović, Bojana
AU  - Đorđević, Brižita
AU  - Milovanović, Srđan
AU  - Skrivanj, Sandra
AU  - Pavlović, Zoran
AU  - Stefanović, Aleksandra
AU  - Kotur-Stevuljević, Jelena
PY  - 2013
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1906
AB  - The aim of this study was to determine the plasma selenium (Se), copper (Cu), and zinc (Zn) levels and to evaluate their possible association with metabolic syndrome (MetS) components in patients with schizophrenia. The study group consisted of 60 patients with schizophrenia and 60 sex- and age-matched healthy controls. Anthropometric measurements, blood pressure, and biochemical analysis of fasting blood were performed in all subjects. Patients with schizophrenia had significantly higher plasma Cu concentrations compared with controls (0.97 +/- 0.31 vs. 0.77 +/- 0.32 mg/L, p = 0.001). The plasma Cu concentration showed a positive correlation with plasma glucose and diastolic blood pressure in the patient groups (r (s) = 0.263, p  lt  0.05 and r (s) = 0.272, p  lt  0.05, respectively). The plasma Se level correlated positive with MetS score (r (s) = 0.385, p  lt  0.01), waist circumference (r (s) = 0.344, p  lt  0.05), plasma glucose (r (s) = 0.319, p  lt  0.05), and triglyceride concentrations (r (s) = 0.462, p  lt  0.001) in patients with schizophrenia. Plasma Zn did not correlate with any of the MetS components. These results suggest that alterations in plasma Cu and Se levels in medicated patients with schizophrenia could be associated with metabolic risk factors.
PB  - Humana Press Inc, Totowa
T2  - Biological Trace Element Research
T1  - Selenium, Zinc, and Copper Plasma Levels in Patients with Schizophrenia: Relationship with Metabolic Risk Factors
VL  - 156
IS  - 1-3
SP  - 22
EP  - 28
DO  - 10.1007/s12011-013-9842-1
ER  - 

@article{
author = "Vidović, Bojana and Đorđević, Brižita and Milovanović, Srđan and Skrivanj, Sandra and Pavlović, Zoran and Stefanović, Aleksandra and Kotur-Stevuljević, Jelena",
year = "2013",
abstract = "The aim of this study was to determine the plasma selenium (Se), copper (Cu), and zinc (Zn) levels and to evaluate their possible association with metabolic syndrome (MetS) components in patients with schizophrenia. The study group consisted of 60 patients with schizophrenia and 60 sex- and age-matched healthy controls. Anthropometric measurements, blood pressure, and biochemical analysis of fasting blood were performed in all subjects. Patients with schizophrenia had significantly higher plasma Cu concentrations compared with controls (0.97 +/- 0.31 vs. 0.77 +/- 0.32 mg/L, p = 0.001). The plasma Cu concentration showed a positive correlation with plasma glucose and diastolic blood pressure in the patient groups (r (s) = 0.263, p  lt  0.05 and r (s) = 0.272, p  lt  0.05, respectively). The plasma Se level correlated positive with MetS score (r (s) = 0.385, p  lt  0.01), waist circumference (r (s) = 0.344, p  lt  0.05), plasma glucose (r (s) = 0.319, p  lt  0.05), and triglyceride concentrations (r (s) = 0.462, p  lt  0.001) in patients with schizophrenia. Plasma Zn did not correlate with any of the MetS components. These results suggest that alterations in plasma Cu and Se levels in medicated patients with schizophrenia could be associated with metabolic risk factors.",
publisher = "Humana Press Inc, Totowa",
journal = "Biological Trace Element Research",
title = "Selenium, Zinc, and Copper Plasma Levels in Patients with Schizophrenia: Relationship with Metabolic Risk Factors",
volume = "156",
number = "1-3",
pages = "22-28",
doi = "10.1007/s12011-013-9842-1"
}

Vidović, B., Đorđević, B., Milovanović, S., Skrivanj, S., Pavlović, Z., Stefanović, A.,& Kotur-Stevuljević, J.. (2013). Selenium, Zinc, and Copper Plasma Levels in Patients with Schizophrenia: Relationship with Metabolic Risk Factors. in Biological Trace Element Research
Humana Press Inc, Totowa., 156(1-3), 22-28.
https://doi.org/10.1007/s12011-013-9842-1

Vidović B, Đorđević B, Milovanović S, Skrivanj S, Pavlović Z, Stefanović A, Kotur-Stevuljević J. Selenium, Zinc, and Copper Plasma Levels in Patients with Schizophrenia: Relationship with Metabolic Risk Factors. in Biological Trace Element Research. 2013;156(1-3):22-28.
doi:10.1007/s12011-013-9842-1 .

Vidović, Bojana, Đorđević, Brižita, Milovanović, Srđan, Skrivanj, Sandra, Pavlović, Zoran, Stefanović, Aleksandra, Kotur-Stevuljević, Jelena, "Selenium, Zinc, and Copper Plasma Levels in Patients with Schizophrenia: Relationship with Metabolic Risk Factors" in Biological Trace Element Research, 156, no. 1-3 (2013):22-28,
https://doi.org/10.1007/s12011-013-9842-1 . .